John Duke Biography and Net Worth

President and Chief Executive Officer of Harvard Bioscience

On July 16, 2025, the Board of Directors of the Company appointed John Duke to serve as President and Chief Executive Officer effective July 28, 2025. In this role, Mr. Duke will serve as the Company’s principal executive officer. Mr. Duke has served as a member of the Board since June 2025. From January 2024 until immediately prior to becoming Chief Executive Officer of the Company, Mr. Duke was Chief Executive Officer of Plastic Molding Technology, a plastics manufacturing company providing broad capabilities, including injection molding and thermoforming, coupled with technical expertise. From February 2021 until April 2023, Mr. Duke served as Chief Business Officer for Lyten, an Advanced Materials company that transforms greenhouse gases into Lyten 3D Graphene™ and developing innovative products across multiple industries. Prior to Lyten, Mr. Duke served in multiple positions at Corning Incorporated, one of the world's leading innovators in materials science, including Corporate Vice President, Corporate Officer, VP & GM - Glass Microsystems from April 2017 to February 2021, Vice President Sales and Marketing, Gorilla Glass from April 2016 to April 2017 and Vice President, Business Operations, Corning Life Sciences from October 2012 to March 2016. Mr. Duke holds a BS in Materials Science from University of Utah and an MBA from Harvard Business School.

What is John D. Duke's net worth?: The estimated net worth of John D. Duke is at least $838.32 thousand as of March 16th, 2026. Mr. Duke owns 105,000 shares of Harvard Bioscience stock worth more than $838,320 as of September 25th. This net worth evaluation does not reflect any other assets that Mr. Duke may own. Learn More about John D. Duke's net worth.
How do I contact John D. Duke?: The corporate mailing address for Mr. Duke and other Harvard Bioscience executives is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. Harvard Bioscience can also be reached via phone at (508) 893-8999 and via email at [email protected]. Learn More on John D. Duke's contact information.
Has John D. Duke been buying or selling shares of Harvard Bioscience?: John D. Duke has not been actively trading shares of Harvard Bioscience over the course of the past ninety days. Most recently, on Monday, March 16th, John D. Duke bought 5,000 shares of Harvard Bioscience stock. The stock was acquired at an average cost of $5.01 per share, with a total value of $25,050.00. Following the completion of the transaction, the chief executive officer now directly owns 105,000 shares of the company's stock, valued at $526,050. Learn More on John D. Duke's trading history.
Who are Harvard Bioscience's active insiders?: Harvard Bioscience's insider roster includes John Duke (President and Chief Executive Officer), and James Green (CEO). Learn More on Harvard Bioscience's active insiders.
Are insiders buying or selling shares of Harvard Bioscience?: During the last twelve months, Harvard Bioscience insiders bought shares 4 times. They purchased a total of 36,000 shares worth more than $177,353.50. The most recent insider tranaction occured on March, 17th when Director William Snider bought 8,475 shares worth more than $41,103.75. Insiders at Harvard Bioscience own 17.0% of the company. Learn More about insider trades at Harvard Bioscience.
Information on this page was last updated on 3/17/2026.

John D. Duke Insider Trading History at Harvard Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/16/2026	Buy	5,000	$5.01	$25,050.00	105,000

John D. Duke Buying and Selling Activity at Harvard Bioscience

Harvard Bioscience Company Overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Today's Range

Now: $8.01

$7.92

$8.05

50 Day Range

MA: $7.15

$5.92

$8.20

2 Week Range

Now: $8.01

$3.75

$9.40

Volume

2,963 shs

Average Volume

35,238 shs

Market Capitalization

$36.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53